Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission
Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver
tumor-killing substances to them, without harming normal cells. Drugs used in chemotherapy
use different ways to stop cancer cells from dividing so they stop growing or die. Combining
chemotherapy with monoclonal antibody therapy may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus monoclonal antibody
therapy in treating patients with acute promyelocytic leukemia in remission.